Statement: at least 2 participants of the primary trial, at least one from each cohort, had a progression-free survival of 324 days
Primary_evidence: Outcome Measurement:    Progression-Free Survival (PFS)   Progression-free survival will be measured from Day 1 of study drug administration to disease progression defined by Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions   Time frame: every 8 weeks until progressive disease, expected average of 18 months Results 1:    Arm/Group Title: Paclitaxel/Bevacizumab/Everolimus   Arm/Group Description: Systemic Therapy   Overall Number of Participants Analyzed: 56   Median (95% Confidence Interval)   Unit of Measure: months  9.1        (6.8 to 10.8) Results 2:    Arm/Group Title: Paclitaxel/Bevacizumab/Placebo   Arm/Group Description: Systemic Therapy   Overall Number of Participants Analyzed: 57   Median (95% Confidence Interval)   Unit of Measure: months  7.1        (5.6 to 10.8)